Zurück zum Inhalt

Sichelzellerkrankung (Kinder- und Jugendmedizin)

Vermeidung von Krisensituationen

Pharmakologische Aktivierung des fetalen Hämoglobins

Pharmacotherapy in sickle cell disease—state of the art and future prospects. (öffnet neues Fenster)

Hankins J, Aygun B.

Quelle‎: Br J Haematol 2009;145(3):296-308.

Indiziert‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

https://www.ncbi.nlm.nih.gov/pubmed/19222472 (öffnet neues Fenster)

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. (öffnet neues Fenster)

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Quelle‎: Blood 2005;106(7):2269-75.

Indiziert‎: PubMed 16172253

DOI‎: 10.1182/Blood-2004-12-4973

https://www.ncbi.nlm.nih.gov/pubmed/16172253 (öffnet neues Fenster)

Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. (öffnet neues Fenster)

John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE

Quelle‎: N Engl J Med 2020;382(26):2524-33.

Indiziert‎: PubMed 32579813

DOI‎: 10.1056/NEJMoa2000146

https://www.ncbi.nlm.nih.gov/pubmed/32579813 (öffnet neues Fenster)

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. (öffnet neues Fenster)

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Quelle‎: Br J Haematol 2013;161(6):852-60.

Indiziert‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

https://www.ncbi.nlm.nih.gov/pubmed/23590693 (öffnet neues Fenster)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. (öffnet neues Fenster)

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Quelle‎: Arch Dis Child 2013;98(11):908-14.

Indiziert‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

https://www.ncbi.nlm.nih.gov/pubmed/23995076 (öffnet neues Fenster)

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. (öffnet neues Fenster)

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Quelle‎: Pediatrics 2008;122(6):1332-42.

Indiziert‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

https://www.ncbi.nlm.nih.gov/pubmed/19047254 (öffnet neues Fenster)

Impact of hydroxyurea on clinical events in the BABY HUG trial. (öffnet neues Fenster)

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Quelle‎: Blood 2012;120(22):4304-10.

Indiziert‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

https://www.ncbi.nlm.nih.gov/pubmed/22915643 (öffnet neues Fenster)

Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. (öffnet neues Fenster)

Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators

Quelle‎: N Engl J Med 2019;380(2):121-31.

Indiziert‎: PubMed 30501550

DOI‎: 10.1056/NEJMoa1813598

https://www.ncbi.nlm.nih.gov/pubmed/30501550 (öffnet neues Fenster)

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. (öffnet neues Fenster)

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Quelle‎: J Pediatr 2002;140(2):225-9.

Indiziert‎: PubMed 11865275

DOI‎: 10.1067/mpd.2002.121383

https://www.ncbi.nlm.nih.gov/pubmed/11865275 (öffnet neues Fenster)

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. (öffnet neues Fenster)

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Quelle‎: Pediatrics 2013;132(4):677-83.

Indiziert‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

https://www.ncbi.nlm.nih.gov/pubmed/23999955 (öffnet neues Fenster)

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). (öffnet neues Fenster)

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Quelle‎: Lancet 2011;377(9778):1663-72.

Indiziert‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

https://www.ncbi.nlm.nih.gov/pubmed/21571150 (öffnet neues Fenster)

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. (öffnet neues Fenster)

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Quelle‎: Lancet 2016;387(10019):661-70.

Indiziert‎: PubMed 26670617

https://www.ncbi.nlm.nih.gov/pubmed/26670617 (öffnet neues Fenster)

How I use hydroxyurea to treat young patients with sickle cell anemia. (öffnet neues Fenster)

Ware RE.

Quelle‎: Blood 2010;115(26):5300-11.

Indiziert‎: PubMed 20223921

DOI‎: 10.1182/blood-2009-04-146852

https://www.ncbi.nlm.nih.gov/pubmed/20223921 (öffnet neues Fenster)

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. (öffnet neues Fenster)

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Quelle‎: Blood 2004;103(6):2039-45.

Indiziert‎: PubMed 14630791

DOI‎: 10.1182/blood-2003-07-2475

https://www.ncbi.nlm.nih.gov/pubmed/14630791 (öffnet neues Fenster)

Prävention von Infektionen und anderen Komplikationen

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (öffnet neues Fenster)

Hirst C, Owusu-Ofori S.

Quelle‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Indiziert‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (öffnet neues Fenster)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (öffnet neues Fenster)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Quelle‎: Lancet Haematol 2021;8(5):e323-33.

Indiziert‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (öffnet neues Fenster)

Sickle cell disease. (öffnet neues Fenster)

Meremikwu MM, Okomo U.

Quelle‎: BMJ Clin Evid 2011;02:2402.

Indiziert‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (öffnet neues Fenster)

A phase 3 trial of l-glutamine in sickle cell disease. (öffnet neues Fenster)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Quelle‎: N Engl J Med 2018;379(3):226-35.

Indiziert‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (öffnet neues Fenster)

Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. (öffnet neues Fenster)

Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo L, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham TS, Ware RE

Quelle‎: Blood. 2023 23;141(12):1402-10.

Indiziert‎: PubMed 36375125

DOI‎: 10.1182/blood.2022017051

https://pubmed.ncbi.nlm.nih.gov/36375125/ (öffnet neues Fenster)

Malaria chemoprophylaxis in sickle cell disease. (öffnet neues Fenster)

Oniyangi O, Omari AA.

Quelle‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Indiziert‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (öffnet neues Fenster)